[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100477154":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":33,"locations":43,"responsibleParty":69,"collaborators":73,"id":81,"slug":32,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":32,"eligibilityCriteria":85,"healthyVolunteers":82,"sex":86,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":32,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":99,"overallStatus":45,"whyStopped":32,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Shanghai Pulmonary Hospital, Shanghai, China","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Vγ2Vδ2 T lymphocyte-based immunotherapy +Treatment regimens for MDR-TB","EXPERIMENTAL","Treatment was based on the principles of the WHO guidelines for the treatment of drug-resistant tuberculosis, with the addition of immunotherapy：zoledronic acid and recombinant human interleukin 2",[13,14],"Drug: Vγ2Vδ2 T lymphocyte-based immunotherapy","Drug: Treatment regimens for MDR-TB",{"label":16,"type":17,"description":18,"interventionNames":19},"Treatment regimens for MDR-TB","ACTIVE_COMPARATOR","Treatment regimens was based on the principles of the WHO guidelines for the treatment of drug-resistant tuberculosis.",[14],[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Vγ2Vδ2 T lymphocyte-based immunotherapy","Intravenous injection of zoledronic acid, followed by a subcutaneous injection recombinant human interleukin. Zoledronic acid was administered 3 times and recombinant human interleukin was administered 10 times for a total of 6 months.",[9],[27],"Drug combination (zoledronic acid\u002Finterleukin 2)",{"type":22,"name":16,"description":18,"armGroupLabels":29,"otherNames":30},[16,9],[31],"Treatment regimen for MDR-TB using WHO guidelines",null,[34,40],{"name":35,"role":36,"phone":37,"phoneExt":38,"email":39},"Sha Wei","CONTACT","+8602165115006","2017","13671758200@126.com",{"name":41,"role":36,"phone":37,"phoneExt":38,"email":42},"Liu Yidian","13816676933@139.com",[44,61],{"facility":5,"status":45,"city":46,"state":32,"zip":47,"country":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"RECRUITING","Shanghai","200433","China",{"type":50,"coordinates":51},"Point",[52,53],121.45806,31.22222,{"lat":53,"lon":52},[56,58],{"name":57,"role":36,"phone":37,"phoneExt":38,"email":39},"sha wei",{"name":59,"role":36,"phone":37,"phoneExt":60,"email":42},"liu yidian","2011",{"facility":62,"status":45,"city":46,"state":32,"zip":32,"country":48,"cosmosGeoPoint":63,"geoPoint":65,"contacts":66},"Shanghai Pulmonary Hospital",{"type":50,"coordinates":64},[52,53],{"lat":53,"lon":52},[67],{"name":68,"role":36,"phone":37,"phoneExt":38,"email":42},"Liu yidian",{"type":70,"investigatorFullName":71,"investigatorTitle":72,"investigatorAffiliation":5,"oldNameTitle":32,"oldOrganization":32},"PRINCIPAL_INVESTIGATOR","Wei Sha MD & PhD","Director, Head of Tuberculosis Department,Shanghai Pulmonary Hospital, Principal Investigator, Clinical Professor",[74,77,79],{"name":75,"class":76},"Shanghai Public Health Clinical Center","OTHER_GOV",{"name":78,"class":6},"Huashan Hospital",{"name":80,"class":6},"No.85 Hospital, Changning, Shanghai, China","100477154",false,"NCT05493267","A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB","Inclusion Criteria:\n\n* RR-TB\u002FMDR-TB (resistant to at least isoniazid and rifampicin).\n* Poor efficacy of the original treatment regimen or no response to treatment or less than 4 effective drugs.\n\nExclusion Criteria:\n\n* Immunosuppression due to co-morbidities, such as immune system disorders, tumors, etc.\n* Test confirms poor response to ZOL and IL-2 stimulation.","ALL","18 Years","65 Years",{"count":90,"type":91},30,"ESTIMATED","INTERVENTIONAL",[94],"PHASE4","A Exploratory Study of drug combination (zoledronic acid\u002Finterleukin 2) that specifically amplifies Vγ2Vδ2 T cells in combination with anti-tuberculosis chemotherapy for the treatment of MDR-TB.",[97,98],"MDR-TB","Immunotherapy",[100],"MDR-TB；Immunotherapy；","2022-08-08",{"date":103,"type":104},"2022-08-10","ACTUAL",{"date":106,"type":104},"2022-08-03",{"date":108,"type":91},"2027-08-03",{"name":5,"class":6},2]